257 related articles for article (PubMed ID: 21281486)
21. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma.
Vicente D; Lee AJ; Hall CS; Lucci A; Lee JE; Kim MP; Katz MHG; Hurd MW; Maitra A; Rhim Md AD; Tzeng CD
J Surg Res; 2019 Nov; 243():90-99. PubMed ID: 31170555
[TBL] [Abstract][Full Text] [Related]
22. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
[TBL] [Abstract][Full Text] [Related]
23. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer.
Guller U; Zajac P; Schnider A; Bösch B; Vorburger S; Zuber M; Spagnoli GC; Oertli D; Maurer R; Metzger U; Harder F; Heberer M; Marti WR
Ann Surg; 2002 Dec; 236(6):768-75; discussion 775-6. PubMed ID: 12454515
[TBL] [Abstract][Full Text] [Related]
24. Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.
Leick KM; Tomanek-Chalkley A; Coleman KL; Chan CHF
Ann Surg Oncol; 2023 Oct; 30(11):6652-6660. PubMed ID: 37303025
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer.
Tanemura M; Furukawa K; Mikamori M; Asaoka T; Yasuoka H; Marukawa D; Urata Y; Yamada D; Kobayashi S; Eguchi H
Sci Rep; 2024 May; 14(1):10199. PubMed ID: 38702437
[TBL] [Abstract][Full Text] [Related]
26. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of occult tumor cells obtained by peritoneal lavage in patients with resectable pancreatic cancer and no ascites: A systematic review.
Steen W; Blom R; Busch O; Gerhards M; Besselink M; Dijk F; Festen S
J Surg Oncol; 2016 Nov; 114(6):743-751. PubMed ID: 27642007
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
29. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.
Strati A; Kasimir-Bauer S; Markou A; Parisi C; Lianidou ES
Breast Cancer Res; 2013 Mar; 15(2):R20. PubMed ID: 23497487
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy.
Giampieri R; Piva F; Occhipinti G; Bittoni A; Righetti A; Pagliaretta S; Murrone A; Bianchi F; Amantini C; Giulietti M; Ricci G; Principato G; Santoni G; Berardi R; Cascinu S
PLoS One; 2019; 14(5):e0215990. PubMed ID: 31048929
[TBL] [Abstract][Full Text] [Related]
31. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
32. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.
Fong D; Moser P; Kasal A; Seeber A; Gastl G; Martowicz A; Wurm M; Mian C; Obrist P; Mazzoleni G; Spizzo G
Histopathology; 2014 Apr; 64(5):683-92. PubMed ID: 24117877
[TBL] [Abstract][Full Text] [Related]
33. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.
Hinz S; Hendricks A; Wittig A; Schafmayer C; Tepel J; Kalthoff H; Becker T; Röder C
BMC Cancer; 2017 Jan; 17(1):53. PubMed ID: 28086834
[TBL] [Abstract][Full Text] [Related]
34. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
36. Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma.
Lewis HL; Chakedis JM; Talbert E; Haverick E; Rajasekera P; Hart P; Bloomston M; Dillhoff M; Pawlik TM; Guttridge D; Schmidt CR
J Surg Oncol; 2018 May; 117(6):1260-1266. PubMed ID: 29205349
[TBL] [Abstract][Full Text] [Related]
37. Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma.
Huang Y; Ren GP; Xu C; Dong SF; Wang Y; Gan Y; Zhu L; Feng TY
BMC Cancer; 2014 Jul; 14():479. PubMed ID: 24989027
[TBL] [Abstract][Full Text] [Related]
38. High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Song Y; Tang MY; Chen W; Wang Z; Wang SL
Dis Markers; 2020; 2020():7656031. PubMed ID: 33029256
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of recurrence pattern after resection for pancreatic cancer.
Tanaka M; Mihaljevic AL; Probst P; Heckler M; Klaiber U; Heger U; Büchler MW; Hackert T
Br J Surg; 2019 Nov; 106(12):1590-1601. PubMed ID: 31454073
[TBL] [Abstract][Full Text] [Related]
40. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]